Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad291 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Jakob Albrethsen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Insulin, Prostatic Neoplasms, Testosterone. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Innovation Fund Denmark.
Abstract (Originalsprache)
Background
Serum insulin-like factor 3 (INSL3) is a Leydig cell biomarker, but little is known about the circulating concentration of INSL3 during hypothalamus-pituitary-testicular suppression.
Aim
To study the concomitant changes in serum concentrations of INSL3, testosterone, and LH during experimental and therapeutic testicular suppression.
Methods
We included serum samples from 3 different cohorts comprising subjects before and after testicular suppression: (1) 6 healthy young men who were treated with androgens (Sustanon, Aspen Pharma, Dublin, Ireland); 2) 10 transgender girls (male sex assigned at birth) who were treated with 3-monthly GnRH agonist injections (Leuprorelinacetat, Abacus Medicine, Copenhagen, Denmark); and (3) 55 patients with prostate cancer who were randomized to surgical castration (bilateral subcapsular orchiectomy) or treatment with GnRH agonist (Triptorelin, Ipsen Pharma, Kista, Sweden). Serum INSL3 and testosterone concentrations were quantified in stored serum samples using validated liquid chromatography-tandem mass spectrometry methodologies, and LH was measured by an ultrasensitive immunoassay.
Results
The circulating concentrations of INSL3, testosterone, and LH decreased during experimental testicular suppression in healthy young men by Sustanon injections and subsequently returned to baseline levels after release of suppression. All 3 hormones decreased during therapeutic hormonal hypothalamus-pituitary-testicular suppression in transgender girls and in patients with prostate cancer.
Conclusion
INSL3 resembles testosterone as a sensitive marker of testicular suppression and reflects Leydig cell function, also during exposure to exogenous testosterone. Serum INSL3 measurements may complement testosterone as a Leydig cell marker in male reproductive disorders, during therapeutic testicular suppression as well as in surveillance of illicit use of androgens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark.
- International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, 2100 Copenhagen, Denmark.
- Department of Endocrinology, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark.
- Department of Nutrition, Exercise and Sports, University of Copenhagen, 2100 Copenhagen, Denmark.
- Science and Research, Anti Doping Denmark, 2660 Brøndby, Denmark.
ORCID-Profile: Jakob Albrethsen, Caroline Kistorp, Anders Juul
Förderung
- Innovation Fund Denmark
Zitieren
APA
Albrethsen, J., Østergren, P. B., Norup, P. B., Sønksen, J., Fode, M., Kistorp, C., Nordsborg, N. B., Solheim, S. A., Mørkeberg, J., Main, K. M., & Juul, A. (2023). Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad291
Vancouver
Albrethsen J, Østergren PB, Norup PB, Sønksen J, Fode M, Kistorp C, et al. Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad291
BibTeX
@article{Albrethsen2023,
author = {Albrethsen, Jakob and Østergren, Peter Busch and Norup, Pernille Badsberg and Sønksen, Jens and Fode, Mikkel and Kistorp, Caroline and Nordsborg, Nikolai B and Solheim, Sara Amalie and Mørkeberg, Jakob and Main, Katharina M and Juul, Anders},
title = {Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad291}
}
EUVIMED